332 related articles for article (PubMed ID: 33253997)
21. [Cabozantinib: Mechanism of action, efficacy and indications].
Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
[TBL] [Abstract][Full Text] [Related]
22. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
[TBL] [Abstract][Full Text] [Related]
23. Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence.
Bergerot P; Lamb P; Wang E; Pal SK
Mol Cancer Ther; 2019 Dec; 18(12):2185-2193. PubMed ID: 31792125
[TBL] [Abstract][Full Text] [Related]
24. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
25. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
[TBL] [Abstract][Full Text] [Related]
26. Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes.
Venugopal B; Pillai M; Powles T; Savage P; Michael A; Fife K; Klair B; Perrot V; Szabados B
Clin Genitourin Cancer; 2022 Feb; 20(1):94-94.e10. PubMed ID: 34802966
[TBL] [Abstract][Full Text] [Related]
27. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.
Peverelli G; Raimondi A; Ratta R; Verzoni E; Bregni M; Cortesi E; Cartenì G; Fornarini G; Facchini G; Buti S; Galli L; Tucci M; Prisciandaro M; Procopio G
Clin Genitourin Cancer; 2019 Aug; 17(4):291-298. PubMed ID: 31178240
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
Procopio G; Prisciandaro M; Iacovelli R; Cortesi E; Fornarini G; Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; Mecozzi A; Ratta R; Sternberg CN; Verzoni E
Clin Genitourin Cancer; 2018 Aug; 16(4):e945-e951. PubMed ID: 29753637
[TBL] [Abstract][Full Text] [Related]
29. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
[TBL] [Abstract][Full Text] [Related]
30. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
[TBL] [Abstract][Full Text] [Related]
31. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.
Rassy E; Cerbone L; Auclin E; Benchimoll-Zouari A; Flippot R; Alves Costa Silva C; Colomba E; Geraud A; Guida A; Mir O; Combarel D; Paci A; Escudier B; Albiges L
Oncologist; 2021 May; 26(5):389-396. PubMed ID: 33554383
[TBL] [Abstract][Full Text] [Related]
32. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer.
Krens SD; van Erp NP; Groenland SL; Moes DJAR; Mulder SF; Desar IME; van der Hulle T; Steeghs N; van Herpen CML
BMC Cancer; 2022 Mar; 22(1):228. PubMed ID: 35236333
[TBL] [Abstract][Full Text] [Related]
33. Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma.
Ratta R; Verzoni E; Mennitto A; Pantano F; Martinetti A; Raimondi A; Sepe P; Sottotetti E; Mennitto R; Morelli D; Santini D; de Braud FG; Procopio G
Tumori; 2021 Dec; 107(6):542-549. PubMed ID: 33153416
[TBL] [Abstract][Full Text] [Related]
34. Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers.
Richter I; Poprach A; Zemankova A; Buchler T; Bartos J; Samal V; Studentova H; Rozsypalova A; Dvorak J; Brom O; Melichar B
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):97-104. PubMed ID: 33252116
[TBL] [Abstract][Full Text] [Related]
35. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
36. Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer.
van Boxtel W; Uijen MJM; Krens SD; Dijkema T; Willems SM; Jonker MA; Pegge SAH; van Engen-van Grunsven ACH; van Herpen CML
Eur J Cancer; 2022 Jan; 161():128-137. PubMed ID: 34920917
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
Martini DJ; Evans ST; Liu Y; Shabto JM; Uner OE; Olsen TA; Brown JT; Russler GA; Yantorni L; Caulfield S; Goldman JM; Nazha B; Harris WB; Master VA; Kucuk O; Carthon BC; Bilen MA
Clin Genitourin Cancer; 2022 Feb; 20(1):53-59. PubMed ID: 34922840
[TBL] [Abstract][Full Text] [Related]
38. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
39. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
40. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).
Mennitto A; Zattarin E; Di Maio M; Bimbatti D; De Giorgi U; Buti S; Santini D; Casadei C; Sorarù M; Messina C; Mucciarini C; Di Lorenzo G; Roviello G; Buttigliero C; Stellato M; Sepe P; Claps M; Guadalupi V; Ottini A; Pignata S; De Braud FG; Verzoni E; Procopio G
Expert Rev Anticancer Ther; 2022 Jan; 22(1):115-121. PubMed ID: 34738499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
